Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: A review of the literature

Jun Iwamoto, Yoshihiro Sato, Tsuyoshi Takeda, Hideo Matsumoto

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Osteoporosis most commonly affects postmenopausal women, placing them at a significant risk of fractures. In particular, hip fractures are an important cause of mortality and morbidity among postmenopausal women. Anti-resorptive therapies that produce greater decreases in bone turnover markers together with greater increases in bone mineral density (BMD) are associated with greater reductions in fracture risk, especially at sites primarily composed of cortical bone such as the hip. Thus, treatment with potent anti-resorptive drugs like alendronate is a strategy for preventing hip fractures in postmenopausal women with osteoporosis. The purpose of this paper is to discuss the efficacy of alendronate against hip fractures and the mechanism for this anti-fracture efficacy in postmenopausal women with osteoporosis. A meta-analysis of randomized controlled trials has shown that alendronate reduces the risk of hip fractures by 55% in postmenopausal women with osteoporosis. According to the analyses of the Fracture Intervention Trial, each 1 standard deviation reduction in a 1-year change in bone-specific alkaline phosphatase (BSAP) is associated with 39% fewer hip fractures in alendronate-treated postmenopausal women, and those with at least 30% reduction in BSAP have a 74% lower risk of hip fractures relative to those with less than 30%. Alendronate is effective in reducing the risk of hip fractures across a spectrum of ages. The mechanism for this anti-fracture efficacy has been clarified; alendronate strongly suppresses bone turnover and subsequently increases hip BMD, decreases cortical porosity, improves parameters of hip structure geometry (cortical thickness, cross-sectional area, section modulus, and buckling ratio), and produces more uniform mineralization (increases the mean degree of mineralization of bone) in cortical bone. A once-weekly regimen of alendronate administration provides better patient compliance and persistence with the treatment than the once-daily dosing regimen, leading to greater efficacy against hip fractures. Thus, the efficacy of alendronate against hip fractures has been confirmed in postmenopausal women with osteoporosis, especially with a once-weekly dosing regimen.

Original languageEnglish
Pages (from-to)483-489
Number of pages7
JournalClinical Interventions in Aging
Volume3
Issue number3
Publication statusPublished - 2008
Externally publishedYes

Fingerprint

Alendronate
Hip Fractures
Osteoporosis
Therapeutics
Bone Remodeling
Bone Density
Alkaline Phosphatase
Hip
Pelvic Bones
Bone and Bones
Physiologic Calcification
Fracture Fixation
Porosity
Patient Compliance
Meta-Analysis
Randomized Controlled Trials
Morbidity

Keywords

  • Bone mineral density
  • Bone turnover
  • Cortical porosity
  • Cortical thickness
  • Hip fracture

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Cite this

Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis : A review of the literature. / Iwamoto, Jun; Sato, Yoshihiro; Takeda, Tsuyoshi; Matsumoto, Hideo.

In: Clinical Interventions in Aging, Vol. 3, No. 3, 2008, p. 483-489.

Research output: Contribution to journalArticle

Iwamoto, Jun ; Sato, Yoshihiro ; Takeda, Tsuyoshi ; Matsumoto, Hideo. / Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis : A review of the literature. In: Clinical Interventions in Aging. 2008 ; Vol. 3, No. 3. pp. 483-489.
@article{5b873e2a269c47379fe713d0dc3d35e1,
title = "Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: A review of the literature",
abstract = "Osteoporosis most commonly affects postmenopausal women, placing them at a significant risk of fractures. In particular, hip fractures are an important cause of mortality and morbidity among postmenopausal women. Anti-resorptive therapies that produce greater decreases in bone turnover markers together with greater increases in bone mineral density (BMD) are associated with greater reductions in fracture risk, especially at sites primarily composed of cortical bone such as the hip. Thus, treatment with potent anti-resorptive drugs like alendronate is a strategy for preventing hip fractures in postmenopausal women with osteoporosis. The purpose of this paper is to discuss the efficacy of alendronate against hip fractures and the mechanism for this anti-fracture efficacy in postmenopausal women with osteoporosis. A meta-analysis of randomized controlled trials has shown that alendronate reduces the risk of hip fractures by 55{\%} in postmenopausal women with osteoporosis. According to the analyses of the Fracture Intervention Trial, each 1 standard deviation reduction in a 1-year change in bone-specific alkaline phosphatase (BSAP) is associated with 39{\%} fewer hip fractures in alendronate-treated postmenopausal women, and those with at least 30{\%} reduction in BSAP have a 74{\%} lower risk of hip fractures relative to those with less than 30{\%}. Alendronate is effective in reducing the risk of hip fractures across a spectrum of ages. The mechanism for this anti-fracture efficacy has been clarified; alendronate strongly suppresses bone turnover and subsequently increases hip BMD, decreases cortical porosity, improves parameters of hip structure geometry (cortical thickness, cross-sectional area, section modulus, and buckling ratio), and produces more uniform mineralization (increases the mean degree of mineralization of bone) in cortical bone. A once-weekly regimen of alendronate administration provides better patient compliance and persistence with the treatment than the once-daily dosing regimen, leading to greater efficacy against hip fractures. Thus, the efficacy of alendronate against hip fractures has been confirmed in postmenopausal women with osteoporosis, especially with a once-weekly dosing regimen.",
keywords = "Bone mineral density, Bone turnover, Cortical porosity, Cortical thickness, Hip fracture",
author = "Jun Iwamoto and Yoshihiro Sato and Tsuyoshi Takeda and Hideo Matsumoto",
year = "2008",
language = "English",
volume = "3",
pages = "483--489",
journal = "Clinical Interventions in Aging",
issn = "1176-9092",
publisher = "Dove Medical Press Ltd.",
number = "3",

}

TY - JOUR

T1 - Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis

T2 - A review of the literature

AU - Iwamoto, Jun

AU - Sato, Yoshihiro

AU - Takeda, Tsuyoshi

AU - Matsumoto, Hideo

PY - 2008

Y1 - 2008

N2 - Osteoporosis most commonly affects postmenopausal women, placing them at a significant risk of fractures. In particular, hip fractures are an important cause of mortality and morbidity among postmenopausal women. Anti-resorptive therapies that produce greater decreases in bone turnover markers together with greater increases in bone mineral density (BMD) are associated with greater reductions in fracture risk, especially at sites primarily composed of cortical bone such as the hip. Thus, treatment with potent anti-resorptive drugs like alendronate is a strategy for preventing hip fractures in postmenopausal women with osteoporosis. The purpose of this paper is to discuss the efficacy of alendronate against hip fractures and the mechanism for this anti-fracture efficacy in postmenopausal women with osteoporosis. A meta-analysis of randomized controlled trials has shown that alendronate reduces the risk of hip fractures by 55% in postmenopausal women with osteoporosis. According to the analyses of the Fracture Intervention Trial, each 1 standard deviation reduction in a 1-year change in bone-specific alkaline phosphatase (BSAP) is associated with 39% fewer hip fractures in alendronate-treated postmenopausal women, and those with at least 30% reduction in BSAP have a 74% lower risk of hip fractures relative to those with less than 30%. Alendronate is effective in reducing the risk of hip fractures across a spectrum of ages. The mechanism for this anti-fracture efficacy has been clarified; alendronate strongly suppresses bone turnover and subsequently increases hip BMD, decreases cortical porosity, improves parameters of hip structure geometry (cortical thickness, cross-sectional area, section modulus, and buckling ratio), and produces more uniform mineralization (increases the mean degree of mineralization of bone) in cortical bone. A once-weekly regimen of alendronate administration provides better patient compliance and persistence with the treatment than the once-daily dosing regimen, leading to greater efficacy against hip fractures. Thus, the efficacy of alendronate against hip fractures has been confirmed in postmenopausal women with osteoporosis, especially with a once-weekly dosing regimen.

AB - Osteoporosis most commonly affects postmenopausal women, placing them at a significant risk of fractures. In particular, hip fractures are an important cause of mortality and morbidity among postmenopausal women. Anti-resorptive therapies that produce greater decreases in bone turnover markers together with greater increases in bone mineral density (BMD) are associated with greater reductions in fracture risk, especially at sites primarily composed of cortical bone such as the hip. Thus, treatment with potent anti-resorptive drugs like alendronate is a strategy for preventing hip fractures in postmenopausal women with osteoporosis. The purpose of this paper is to discuss the efficacy of alendronate against hip fractures and the mechanism for this anti-fracture efficacy in postmenopausal women with osteoporosis. A meta-analysis of randomized controlled trials has shown that alendronate reduces the risk of hip fractures by 55% in postmenopausal women with osteoporosis. According to the analyses of the Fracture Intervention Trial, each 1 standard deviation reduction in a 1-year change in bone-specific alkaline phosphatase (BSAP) is associated with 39% fewer hip fractures in alendronate-treated postmenopausal women, and those with at least 30% reduction in BSAP have a 74% lower risk of hip fractures relative to those with less than 30%. Alendronate is effective in reducing the risk of hip fractures across a spectrum of ages. The mechanism for this anti-fracture efficacy has been clarified; alendronate strongly suppresses bone turnover and subsequently increases hip BMD, decreases cortical porosity, improves parameters of hip structure geometry (cortical thickness, cross-sectional area, section modulus, and buckling ratio), and produces more uniform mineralization (increases the mean degree of mineralization of bone) in cortical bone. A once-weekly regimen of alendronate administration provides better patient compliance and persistence with the treatment than the once-daily dosing regimen, leading to greater efficacy against hip fractures. Thus, the efficacy of alendronate against hip fractures has been confirmed in postmenopausal women with osteoporosis, especially with a once-weekly dosing regimen.

KW - Bone mineral density

KW - Bone turnover

KW - Cortical porosity

KW - Cortical thickness

KW - Hip fracture

UR - http://www.scopus.com/inward/record.url?scp=54949125932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54949125932&partnerID=8YFLogxK

M3 - Article

C2 - 18982918

AN - SCOPUS:54949125932

VL - 3

SP - 483

EP - 489

JO - Clinical Interventions in Aging

JF - Clinical Interventions in Aging

SN - 1176-9092

IS - 3

ER -